SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
SEPTEMBER 4, 1997
Date of Report (Date of earliest event reported)
INTERCARDIA, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)
0-27410 56-1924222
(COMMISSION FILE NO.) (I.R.S. EMPLOYER IDENTIFICATION NO.)
3200 EAST HIGHWAY 54,
CAPE FEAR BUILDING, SUITE 300
P. O. BOX 14287
RESEARCH TRIANGLE PARK, NORTH CAROLINA 27709
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)
(919) 558-8688
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
<PAGE>
Item 5. Other Events.
On September 4, 1997, Intercardia, Inc. acquired 79.6% of the
outstanding stock of Renaissance Cell Technologies, Inc. ("Renaissance") for
$500,000. Renaissance is an early stage company conducting research in the area
of hepatic stem cells. Renaissance has entered into a Sponsored Research
Agreement ("UNC Agreement") with The University of North Carolina at Chapel Hill
("UNC") which grants Renaissance an option for an exclusive worldwide license to
products developed under the UNC Agreement. Renaissance has agreed to reimburse
UNC for costs incurred by UNC in connection with the UNC Agreement in an amount
not to exceed $450,000 per year for a minimum of two years.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERCARDIA, INC.
By: /s/ Richard W. Reichow
Richard W. Reichow
Senior Vice President and Chief Financial Officer
Date: September 5, 1997
